CD14152 placebo

DRUG2 trials

Sponsors

Galderma R&D

Conditions

Moderate-to-severe Atopic DermatitisPrurigo Nodularis

Phase 2

Safety and Efficacy of Nemolizumab in PN

CompletedNCT03181503

Galderma R&DPrurigo Nodularis

Start: 2017-10-02End: 2018-09-26Updated: 2020-02-19

Phase 3

Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to or for Whom Cyclosporine A is Not Medically Advisable

WithdrawnNCT05056779

Galderma R&DModerate-to-severe Atopic Dermatitis

Start: 2023-01-31End: 2023-07-31Updated: 2023-09-21

Related Papers

Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis.

2025-12-17

Validation of the Peak Pruritus Numerical Rating Scale as a Patient-Reported Outcome Measure in Prurigo Nodularis.

2023-08-2412 citations

The Sleep Disturbance Numerical Rating Scale: Content Validity, Psychometric Validation, and Meaningful Within-Patient Change in Prurigo Nodularis.

2023-06-1711 citations

Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis

New England Journal of Medicine2020-02-19264 citations